Seventeen studies evaluated PtDAs designed to support PCa screening decisions (prostate specific antigen testing or digital rectal exam); and three studies addressed PCa treatment (active surveillance, prostatectomy, radiation therapy or medication). Here, KLK3 is linked to posterior cortical atrophy.